ODI Pharma AB

ODI

SE0013409760

Pharmaceuticals

End-of-day quote NORDIC GROWTH MARKET Other stock markets 06:00:00 2024-04-24 pm EDT			5-day change	1st Jan Change
5.7 ^SEK	0.00%		+9.62%	+14.00%

Feb. 22	ODI Pharma AB Reports Earnings Results for the Second Quarter and Six Months Ended December 31, 2023	CI
2023	ODI Pharma Sells CBD Skincare Brand for SEK3 Million	MT

Odi Pharma AB Announces Earnings Results for the Quarter Ended September 30, 2020

November 27, 2020 at 09:23 am EST

ODI Pharma AB (publ) announced earnings results for the quarter ended September 30, 2020. loss per share amounted to SEK 0.08 compared to SEK 0.05 a year ago.

Latest news about ODI Pharma AB

ODI Pharma AB Reports Earnings Results for the Second Quarter and Six Months Ended December 31, 2023	Feb. 22	CI
ODI Pharma Sells CBD Skincare Brand for SEK3 Million	Dec. 06	MT
ODI Pharma AB Reports Earnings Results for the First Quarter Ended September 30, 2023	Nov. 24	CI
ODI Pharma AB Reports Earnings Results for the Fourth Quarter and Full Year Ended June 30, 2023	23-08-24	CI
ODI Pharma’s Stock Soars After Exclusive Supplier Deal With Synoptis Pharma	23-08-07	MT
ODI Phaa AB Enters into Exclusive Collaboration with Synoptis Pharma Sp. Z o.o	23-08-07	CI
ODI Pharma AB Receives Loan Financing of EUR 350,000	23-06-01	CI
ODI Pharma AB Reports Earnings Results for the Third Quarter and Nine Months Ended March 31, 2023	23-05-25	CI
ODI Pharma AB Reports Earnings Results for the Second Quarter and Six Months Ended December 31, 2022	23-02-23	CI
ODI Pharma Receives Approval from the Office for Registration of Medicinal Products, Medical Devices and Biocidal Products in Poland to Distribute and Sell Its Products on the Polish Market	23-01-24	CI
ODI Pharma AB Reports Earnings Results for the First Quarter Ended September 30, 2022	22-11-25	CI
ODI Pharma AB Reports Earnings Results for the Fourth Quarter and Full Year Ended June 30, 2022	22-08-25	CI
ODI Pharma AB Reports Earnings Results for the Third Quarter and Nine Months Ended March 31, 2022	22-05-25	CI
ODI Pharma AB Reports Earnings Results for the Second Quarter and Six Months Ended December 31, 2021	22-02-23	CI
ODI Pharma AB Reports Earnings Results for the First Quarter Ended September 30, 2021	21-11-25	CI
Odi Pharma AB to Launch Kandol, the CBD Skincare Product Line	21-09-28	CI
ODI Pharma AB Reports Earning Results for the Fourth Quarter and Full Year Ended June 30, 2021	21-08-26	CI
ODI Pharma AB Approves the Official Launch of Kandol	21-08-17	CI
Certain Shares of ODI Pharma AB are subject to a Lock-Up Agreement Ending on 23-JUL-2021.	21-07-22	CI
ODI Pharma AB Appoints Thomas Cramer as Head of Sales Cosmetics	21-05-27	CI
ODI Pharma AB Announces Group Earnings Results for the Third Quarter and Nine Months Ended March 31, 2021	21-05-27	CI
ODI Pharma Provides Update on progress in "Project Poland" and "Project Skin"	21-04-21	CI
ODI Pharma AB Reports Group Earnings Results for the Second Quarter and Six Months Ended December 31, 2020	21-02-25	CI
ODI Pharma AB Proceeds with Its Plans and Launches Project Skin	21-01-14	CI
Odi Pharma AB Announces Earnings Results for the Quarter Ended September 30, 2020	20-11-27	CI

Odi Pharma AB (publ) is a Swedish-based pharmaceutical company. The Company is a manufacturer and supplier of medical cannabis products. The business is run through subsidiaries and partners where sales are through wholesale distributors and pharmacies. The products are used for the treatment of, for example, multiple sclerosis, chronic pain and chemotherapy. The Company is located in Stockholm.

Sector

Pharmaceuticals

Calendar

2024-05-29 - Q3 2024 Earnings Release

More about the company

Income Statement Evolution

More financial data

Sector Other Pharmaceuticals

	1st Jan change	Capi.
ODI PHARMA AB	+14.00%	7.97M
NOVO NORDISK A/S	+24.17%	562B
JOHNSON & JOHNSON	-6.33%	358B
MERCK & CO., INC.	+19.90%	322B
ABBVIE INC.	+7.95%	297B
ASTRAZENECA PLC	+13.45%	219B
NOVARTIS AG	+6.04%	199B
ROCHE HOLDING AG	-10.51%	196B
PFIZER, INC.	-12.26%	149B
AMGEN INC.	-6.47%	146B